Rankings
▼
Calendar
DNLI Q3 2022 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q3 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
-32.7% YoY
Gross Profit
$4M
100.0% margin
Operating Income
-$107M
-3020.1% margin
Net Income
-$103M
-2902.5% margin
EPS (Diluted)
$-0.84
QoQ Revenue Growth
-93.2%
Cash Flow
Operating Cash Flow
-$57M
Free Cash Flow
-$63M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.2B
Total Liabilities
$416M
Stockholders' Equity
$811M
Cash & Equivalents
$119M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$5M
-32.7%
Gross Profit
$4M
$5M
-32.7%
Operating Income
-$107M
-$86M
-25.6%
Net Income
-$103M
-$85M
-22.1%
← FY 2022
All Quarters
Q4 2022 →